Switch theme
Sign up to access all valuation multiples
MARX Biotech Co Ltd is a retail company which has developed an O2O and OMO full-channel layout in the online Internet platform and cosmeceutical retail market, and has successfully established itself in the market and Build trust and operational growth on the channel side. It has has established more than three thousand large and small cosmeceutical pharmacies in Taiwan, including: Dashu Pharmacy, Dingding Pharmacy, Cosmed, Watsons, Spring Pharmacy, New Gaoqiao Pharmacy, Anlier Pharmacies, etc.
2021
n/a
LTM Revenue n/a
LTM EBITDA n/a
$93.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
MARX Biotech has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, MARX Biotech achieved revenue of $8.8M and an EBITDA of -$0.3M.
MARX Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See MARX Biotech valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $3.3M | $8.8M | XXX | XXX | XXX |
| Gross Profit | n/a | $2.5M | XXX | XXX | XXX |
| Gross Margin | NaN% | 29% | XXX | XXX | XXX |
| EBITDA | $0.2M | -$0.3M | XXX | XXX | XXX |
| EBITDA Margin | 6% | -4% | XXX | XXX | XXX |
| Net Profit | $0.1M | $0.1M | XXX | XXX | XXX |
| Net Margin | 3% | 1% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, MARX Biotech's stock price is TWD 6 (or $0).
MARX Biotech has current market cap of TWD 3.2B (or $96.4M), and EV of TWD 3.1B (or $93.7M).
See MARX Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $93.7M | $96.4M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, MARX Biotech has market cap of $96.4M and EV of $93.7M.
MARX Biotech's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate MARX Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for MARX Biotech and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $93.7M | XXX | XXX | XXX |
| EV/Revenue | 10.7x | XXX | XXX | XXX |
| EV/EBITDA | -294.9x | XXX | XXX | XXX |
| P/E | -247.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -195.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMARX Biotech's NTM/LTM revenue growth is n/a
MARX Biotech's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, MARX Biotech's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate MARX Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for MARX Biotech and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 162% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -4% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -251% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 69% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 10% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 79% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| Oriola | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MARX Biotech acquired XXX companies to date.
Last acquisition by MARX Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . MARX Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was MARX Biotech founded? | MARX Biotech was founded in 2021. |
| Where is MARX Biotech headquartered? | MARX Biotech is headquartered in Taiwan. |
| Is MARX Biotech publicy listed? | Yes, MARX Biotech is a public company listed on ROCO. |
| What is the stock symbol of MARX Biotech? | MARX Biotech trades under 7731 ticker. |
| When did MARX Biotech go public? | MARX Biotech went public in 2024. |
| Who are competitors of MARX Biotech? | Similar companies to MARX Biotech include e.g. MedPlus India, Pague Menos, Droga Raia, Redcare Pharmacy. |
| What is the current market cap of MARX Biotech? | MARX Biotech's current market cap is $96.4M |
| What is the current revenue growth of MARX Biotech? | MARX Biotech revenue growth between 2023 and 2024 was 162%. |
| Is MARX Biotech profitable? | Yes, MARX Biotech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
